PARP inhibition in vivo blocks alcohol-induced brain neurodegeneration and neuroinflammatory cytosolic phospholipase A2 elevations
Chronic alcoholism promotes brain damage that impairs memory and cognition. High binge alcohol levels in adult rats also cause substantial neurodamage to memory-linked regions, notably, the hippocampus (HC) and entorhinal cortex (ECX). Concurrent with neurodegeneration, alcohol elevates poly (ADP-ri...
Gespeichert in:
| Veröffentlicht in: | Neurochemistry international 2019-10, Vol.129, p.104497-104497, Article 104497 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 104497 |
|---|---|
| container_issue | |
| container_start_page | 104497 |
| container_title | Neurochemistry international |
| container_volume | 129 |
| creator | Kouzoukas, Dimitrios E. Schreiber, Jennifer A. Tajuddin, Nuzhath F. Kaja, Simon Neafsey, Edward J. Kim, Hee-Yong Collins, Michael A. |
| description | Chronic alcoholism promotes brain damage that impairs memory and cognition. High binge alcohol levels in adult rats also cause substantial neurodamage to memory-linked regions, notably, the hippocampus (HC) and entorhinal cortex (ECX). Concurrent with neurodegeneration, alcohol elevates poly (ADP-ribose) polymerase-1 (PARP-1) and cytosolic phospholipase A2 (cPLA2) levels. PARP-1 triggers necrosis when excessively activated, while cPLA2 liberates neuroinflammatory ω-6 arachidonic acid. Inhibitors of PARP exert in vitro neuroprotection while suppressing cPLA2 elevations in alcohol-treated HC-ECX slice cultures. Here, we examined in vivo neuroprotection and cPLA2 suppression by the PARP inhibitor, veliparib, in a recognized adult rat model of alcohol-binging. Adult male rats received Vanilla Ensure containing alcohol (ethanol, 7.1 ± 0.3 g/kg/day), or control (dextrose) ± veliparib (25 mg/kg/day), by gavage 3x daily for 4 days. Rats were sacrificed on the morning after the final binge. HC and ECX neurodegeneration was assessed in fixed sections by Fluoro-Jade B (FJB) staining. Dorsal HC, ventral HC, and ECX cPLA2 levels were quantified by immunoblotting. Like other studies using this model, alcohol binges elevated FJB staining in the HC (dentate gyrus) and ECX, indicating neurodegeneration. Veliparib co-treatment significantly reduced dentate gyrus and ECX neurodegeneration by 79% and 66%, respectively. Alcohol binges increased cPLA2 in the ventral HC by 34% and ECX by 72%, which veliparib co-treatment largely prevented. Dorsal HC cPLA2 levels remained unaffected by alcohol binges, consistent with negligible FJB staining in this brain region. These in vivo results support an emerging key role for PARP in binge alcohol-induced neurodegeneration and cPLA2-related neuroinflammation.
•Alcohol caused neurodegeneration in rat dentate gyrus and lateral entorhinal cortex.•PARP inhibitor treatment (veliparib) blocked alcohol-related neurodegeneration.•Alcohol raised inflammatory cPLA2 in ventral hippocampus and entorhinal cortex.•Veliparib treatment normalized cPLA2 levels in affected brain regions. |
| doi_str_mv | 10.1016/j.neuint.2019.104497 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6760246</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197018619302311</els_id><sourcerecordid>2250630776</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-5aaa678bfea286162c72bd0607fb12175ab88345b0ba622c971692eb24c0c1473</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EotuFN0AoRy5ZbMexkwvSqqJQqVIrBGfLdiZdL4692EmkvfLk9Tal0AsHy9bM_PPP-EPoHcEbggn_uN94mKwfNxSTNocYa8ULtCKNoGUravYSrXJClJg0_Aydp7THGIsW16_RWUVoTVpWr9Dv2-2328L6ndV2tMHnZzHbORTaBfMzFcqZsAuutL6bDHSFjipXZOcYOrgDD1E9yJTvlqj1vVPDoMYQj4U5jiEFZ01x2IWUj7MHlaDY0gIczA_S9Aa96pVL8PbxXqMfl5-_X3wtr2--XF1sr0vDeDWWtVKKi0b3oGjDCadGUN1hjkWvCSWiVrppKlZrrBWn1LSC8JaCpsxgQ5io1ujT0vcw6QE6A36MyslDtIOKRxmUlc8z3u7kXZglFxzTPMMafXhsEMOvCdIoB5sMOKc8hClJSmvMKyzEqZQtpSaGlCL0TzYEyxM-uZcLPnnCJxd8Wfb-3xGfRH94_d0B8kfNFqJMxoLPZGwEM8ou2P873APKSLH8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2250630776</pqid></control><display><type>article</type><title>PARP inhibition in vivo blocks alcohol-induced brain neurodegeneration and neuroinflammatory cytosolic phospholipase A2 elevations</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Kouzoukas, Dimitrios E. ; Schreiber, Jennifer A. ; Tajuddin, Nuzhath F. ; Kaja, Simon ; Neafsey, Edward J. ; Kim, Hee-Yong ; Collins, Michael A.</creator><creatorcontrib>Kouzoukas, Dimitrios E. ; Schreiber, Jennifer A. ; Tajuddin, Nuzhath F. ; Kaja, Simon ; Neafsey, Edward J. ; Kim, Hee-Yong ; Collins, Michael A.</creatorcontrib><description>Chronic alcoholism promotes brain damage that impairs memory and cognition. High binge alcohol levels in adult rats also cause substantial neurodamage to memory-linked regions, notably, the hippocampus (HC) and entorhinal cortex (ECX). Concurrent with neurodegeneration, alcohol elevates poly (ADP-ribose) polymerase-1 (PARP-1) and cytosolic phospholipase A2 (cPLA2) levels. PARP-1 triggers necrosis when excessively activated, while cPLA2 liberates neuroinflammatory ω-6 arachidonic acid. Inhibitors of PARP exert in vitro neuroprotection while suppressing cPLA2 elevations in alcohol-treated HC-ECX slice cultures. Here, we examined in vivo neuroprotection and cPLA2 suppression by the PARP inhibitor, veliparib, in a recognized adult rat model of alcohol-binging. Adult male rats received Vanilla Ensure containing alcohol (ethanol, 7.1 ± 0.3 g/kg/day), or control (dextrose) ± veliparib (25 mg/kg/day), by gavage 3x daily for 4 days. Rats were sacrificed on the morning after the final binge. HC and ECX neurodegeneration was assessed in fixed sections by Fluoro-Jade B (FJB) staining. Dorsal HC, ventral HC, and ECX cPLA2 levels were quantified by immunoblotting. Like other studies using this model, alcohol binges elevated FJB staining in the HC (dentate gyrus) and ECX, indicating neurodegeneration. Veliparib co-treatment significantly reduced dentate gyrus and ECX neurodegeneration by 79% and 66%, respectively. Alcohol binges increased cPLA2 in the ventral HC by 34% and ECX by 72%, which veliparib co-treatment largely prevented. Dorsal HC cPLA2 levels remained unaffected by alcohol binges, consistent with negligible FJB staining in this brain region. These in vivo results support an emerging key role for PARP in binge alcohol-induced neurodegeneration and cPLA2-related neuroinflammation.
•Alcohol caused neurodegeneration in rat dentate gyrus and lateral entorhinal cortex.•PARP inhibitor treatment (veliparib) blocked alcohol-related neurodegeneration.•Alcohol raised inflammatory cPLA2 in ventral hippocampus and entorhinal cortex.•Veliparib treatment normalized cPLA2 levels in affected brain regions.</description><identifier>ISSN: 0197-0186</identifier><identifier>EISSN: 1872-9754</identifier><identifier>DOI: 10.1016/j.neuint.2019.104497</identifier><identifier>PMID: 31251945</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Alcohol ; Alcohol-Induced Disorders, Nervous System - drug therapy ; Alcohol-Induced Disorders, Nervous System - enzymology ; Alcohol-Induced Disorders, Nervous System - prevention & control ; Animals ; Benzimidazoles - pharmacology ; Benzimidazoles - therapeutic use ; Binge Drinking ; Cytosolic phospholipase A2 ; Dentate Gyrus - drug effects ; Dentate Gyrus - enzymology ; Dentate Gyrus - pathology ; Disease Models, Animal ; Entorhinal Cortex - drug effects ; Entorhinal Cortex - enzymology ; Entorhinal Cortex - pathology ; Enzyme Induction - drug effects ; Male ; Nerve Tissue Proteins - biosynthesis ; Nerve Tissue Proteins - genetics ; Neurodegeneration ; Phospholipases A2, Cytosolic - biosynthesis ; Phospholipases A2, Cytosolic - genetics ; Poly(ADP-Ribose) polymerase ; Poly(ADP-ribose) Polymerase Inhibitors - pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use ; Rats ; Rats, Sprague-Dawley ; Veliparib</subject><ispartof>Neurochemistry international, 2019-10, Vol.129, p.104497-104497, Article 104497</ispartof><rights>2019</rights><rights>Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-5aaa678bfea286162c72bd0607fb12175ab88345b0ba622c971692eb24c0c1473</citedby><cites>FETCH-LOGICAL-c463t-5aaa678bfea286162c72bd0607fb12175ab88345b0ba622c971692eb24c0c1473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neuint.2019.104497$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31251945$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kouzoukas, Dimitrios E.</creatorcontrib><creatorcontrib>Schreiber, Jennifer A.</creatorcontrib><creatorcontrib>Tajuddin, Nuzhath F.</creatorcontrib><creatorcontrib>Kaja, Simon</creatorcontrib><creatorcontrib>Neafsey, Edward J.</creatorcontrib><creatorcontrib>Kim, Hee-Yong</creatorcontrib><creatorcontrib>Collins, Michael A.</creatorcontrib><title>PARP inhibition in vivo blocks alcohol-induced brain neurodegeneration and neuroinflammatory cytosolic phospholipase A2 elevations</title><title>Neurochemistry international</title><addtitle>Neurochem Int</addtitle><description>Chronic alcoholism promotes brain damage that impairs memory and cognition. High binge alcohol levels in adult rats also cause substantial neurodamage to memory-linked regions, notably, the hippocampus (HC) and entorhinal cortex (ECX). Concurrent with neurodegeneration, alcohol elevates poly (ADP-ribose) polymerase-1 (PARP-1) and cytosolic phospholipase A2 (cPLA2) levels. PARP-1 triggers necrosis when excessively activated, while cPLA2 liberates neuroinflammatory ω-6 arachidonic acid. Inhibitors of PARP exert in vitro neuroprotection while suppressing cPLA2 elevations in alcohol-treated HC-ECX slice cultures. Here, we examined in vivo neuroprotection and cPLA2 suppression by the PARP inhibitor, veliparib, in a recognized adult rat model of alcohol-binging. Adult male rats received Vanilla Ensure containing alcohol (ethanol, 7.1 ± 0.3 g/kg/day), or control (dextrose) ± veliparib (25 mg/kg/day), by gavage 3x daily for 4 days. Rats were sacrificed on the morning after the final binge. HC and ECX neurodegeneration was assessed in fixed sections by Fluoro-Jade B (FJB) staining. Dorsal HC, ventral HC, and ECX cPLA2 levels were quantified by immunoblotting. Like other studies using this model, alcohol binges elevated FJB staining in the HC (dentate gyrus) and ECX, indicating neurodegeneration. Veliparib co-treatment significantly reduced dentate gyrus and ECX neurodegeneration by 79% and 66%, respectively. Alcohol binges increased cPLA2 in the ventral HC by 34% and ECX by 72%, which veliparib co-treatment largely prevented. Dorsal HC cPLA2 levels remained unaffected by alcohol binges, consistent with negligible FJB staining in this brain region. These in vivo results support an emerging key role for PARP in binge alcohol-induced neurodegeneration and cPLA2-related neuroinflammation.
•Alcohol caused neurodegeneration in rat dentate gyrus and lateral entorhinal cortex.•PARP inhibitor treatment (veliparib) blocked alcohol-related neurodegeneration.•Alcohol raised inflammatory cPLA2 in ventral hippocampus and entorhinal cortex.•Veliparib treatment normalized cPLA2 levels in affected brain regions.</description><subject>Alcohol</subject><subject>Alcohol-Induced Disorders, Nervous System - drug therapy</subject><subject>Alcohol-Induced Disorders, Nervous System - enzymology</subject><subject>Alcohol-Induced Disorders, Nervous System - prevention & control</subject><subject>Animals</subject><subject>Benzimidazoles - pharmacology</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Binge Drinking</subject><subject>Cytosolic phospholipase A2</subject><subject>Dentate Gyrus - drug effects</subject><subject>Dentate Gyrus - enzymology</subject><subject>Dentate Gyrus - pathology</subject><subject>Disease Models, Animal</subject><subject>Entorhinal Cortex - drug effects</subject><subject>Entorhinal Cortex - enzymology</subject><subject>Entorhinal Cortex - pathology</subject><subject>Enzyme Induction - drug effects</subject><subject>Male</subject><subject>Nerve Tissue Proteins - biosynthesis</subject><subject>Nerve Tissue Proteins - genetics</subject><subject>Neurodegeneration</subject><subject>Phospholipases A2, Cytosolic - biosynthesis</subject><subject>Phospholipases A2, Cytosolic - genetics</subject><subject>Poly(ADP-Ribose) polymerase</subject><subject>Poly(ADP-ribose) Polymerase Inhibitors - pharmacology</subject><subject>Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Veliparib</subject><issn>0197-0186</issn><issn>1872-9754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi0EotuFN0AoRy5ZbMexkwvSqqJQqVIrBGfLdiZdL4692EmkvfLk9Tal0AsHy9bM_PPP-EPoHcEbggn_uN94mKwfNxSTNocYa8ULtCKNoGUravYSrXJClJg0_Aydp7THGIsW16_RWUVoTVpWr9Dv2-2328L6ndV2tMHnZzHbORTaBfMzFcqZsAuutL6bDHSFjipXZOcYOrgDD1E9yJTvlqj1vVPDoMYQj4U5jiEFZ01x2IWUj7MHlaDY0gIczA_S9Aa96pVL8PbxXqMfl5-_X3wtr2--XF1sr0vDeDWWtVKKi0b3oGjDCadGUN1hjkWvCSWiVrppKlZrrBWn1LSC8JaCpsxgQ5io1ujT0vcw6QE6A36MyslDtIOKRxmUlc8z3u7kXZglFxzTPMMafXhsEMOvCdIoB5sMOKc8hClJSmvMKyzEqZQtpSaGlCL0TzYEyxM-uZcLPnnCJxd8Wfb-3xGfRH94_d0B8kfNFqJMxoLPZGwEM8ou2P873APKSLH8</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Kouzoukas, Dimitrios E.</creator><creator>Schreiber, Jennifer A.</creator><creator>Tajuddin, Nuzhath F.</creator><creator>Kaja, Simon</creator><creator>Neafsey, Edward J.</creator><creator>Kim, Hee-Yong</creator><creator>Collins, Michael A.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20191001</creationdate><title>PARP inhibition in vivo blocks alcohol-induced brain neurodegeneration and neuroinflammatory cytosolic phospholipase A2 elevations</title><author>Kouzoukas, Dimitrios E. ; Schreiber, Jennifer A. ; Tajuddin, Nuzhath F. ; Kaja, Simon ; Neafsey, Edward J. ; Kim, Hee-Yong ; Collins, Michael A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-5aaa678bfea286162c72bd0607fb12175ab88345b0ba622c971692eb24c0c1473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Alcohol</topic><topic>Alcohol-Induced Disorders, Nervous System - drug therapy</topic><topic>Alcohol-Induced Disorders, Nervous System - enzymology</topic><topic>Alcohol-Induced Disorders, Nervous System - prevention & control</topic><topic>Animals</topic><topic>Benzimidazoles - pharmacology</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Binge Drinking</topic><topic>Cytosolic phospholipase A2</topic><topic>Dentate Gyrus - drug effects</topic><topic>Dentate Gyrus - enzymology</topic><topic>Dentate Gyrus - pathology</topic><topic>Disease Models, Animal</topic><topic>Entorhinal Cortex - drug effects</topic><topic>Entorhinal Cortex - enzymology</topic><topic>Entorhinal Cortex - pathology</topic><topic>Enzyme Induction - drug effects</topic><topic>Male</topic><topic>Nerve Tissue Proteins - biosynthesis</topic><topic>Nerve Tissue Proteins - genetics</topic><topic>Neurodegeneration</topic><topic>Phospholipases A2, Cytosolic - biosynthesis</topic><topic>Phospholipases A2, Cytosolic - genetics</topic><topic>Poly(ADP-Ribose) polymerase</topic><topic>Poly(ADP-ribose) Polymerase Inhibitors - pharmacology</topic><topic>Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Veliparib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kouzoukas, Dimitrios E.</creatorcontrib><creatorcontrib>Schreiber, Jennifer A.</creatorcontrib><creatorcontrib>Tajuddin, Nuzhath F.</creatorcontrib><creatorcontrib>Kaja, Simon</creatorcontrib><creatorcontrib>Neafsey, Edward J.</creatorcontrib><creatorcontrib>Kim, Hee-Yong</creatorcontrib><creatorcontrib>Collins, Michael A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurochemistry international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kouzoukas, Dimitrios E.</au><au>Schreiber, Jennifer A.</au><au>Tajuddin, Nuzhath F.</au><au>Kaja, Simon</au><au>Neafsey, Edward J.</au><au>Kim, Hee-Yong</au><au>Collins, Michael A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PARP inhibition in vivo blocks alcohol-induced brain neurodegeneration and neuroinflammatory cytosolic phospholipase A2 elevations</atitle><jtitle>Neurochemistry international</jtitle><addtitle>Neurochem Int</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>129</volume><spage>104497</spage><epage>104497</epage><pages>104497-104497</pages><artnum>104497</artnum><issn>0197-0186</issn><eissn>1872-9754</eissn><abstract>Chronic alcoholism promotes brain damage that impairs memory and cognition. High binge alcohol levels in adult rats also cause substantial neurodamage to memory-linked regions, notably, the hippocampus (HC) and entorhinal cortex (ECX). Concurrent with neurodegeneration, alcohol elevates poly (ADP-ribose) polymerase-1 (PARP-1) and cytosolic phospholipase A2 (cPLA2) levels. PARP-1 triggers necrosis when excessively activated, while cPLA2 liberates neuroinflammatory ω-6 arachidonic acid. Inhibitors of PARP exert in vitro neuroprotection while suppressing cPLA2 elevations in alcohol-treated HC-ECX slice cultures. Here, we examined in vivo neuroprotection and cPLA2 suppression by the PARP inhibitor, veliparib, in a recognized adult rat model of alcohol-binging. Adult male rats received Vanilla Ensure containing alcohol (ethanol, 7.1 ± 0.3 g/kg/day), or control (dextrose) ± veliparib (25 mg/kg/day), by gavage 3x daily for 4 days. Rats were sacrificed on the morning after the final binge. HC and ECX neurodegeneration was assessed in fixed sections by Fluoro-Jade B (FJB) staining. Dorsal HC, ventral HC, and ECX cPLA2 levels were quantified by immunoblotting. Like other studies using this model, alcohol binges elevated FJB staining in the HC (dentate gyrus) and ECX, indicating neurodegeneration. Veliparib co-treatment significantly reduced dentate gyrus and ECX neurodegeneration by 79% and 66%, respectively. Alcohol binges increased cPLA2 in the ventral HC by 34% and ECX by 72%, which veliparib co-treatment largely prevented. Dorsal HC cPLA2 levels remained unaffected by alcohol binges, consistent with negligible FJB staining in this brain region. These in vivo results support an emerging key role for PARP in binge alcohol-induced neurodegeneration and cPLA2-related neuroinflammation.
•Alcohol caused neurodegeneration in rat dentate gyrus and lateral entorhinal cortex.•PARP inhibitor treatment (veliparib) blocked alcohol-related neurodegeneration.•Alcohol raised inflammatory cPLA2 in ventral hippocampus and entorhinal cortex.•Veliparib treatment normalized cPLA2 levels in affected brain regions.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31251945</pmid><doi>10.1016/j.neuint.2019.104497</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0197-0186 |
| ispartof | Neurochemistry international, 2019-10, Vol.129, p.104497-104497, Article 104497 |
| issn | 0197-0186 1872-9754 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6760246 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Alcohol Alcohol-Induced Disorders, Nervous System - drug therapy Alcohol-Induced Disorders, Nervous System - enzymology Alcohol-Induced Disorders, Nervous System - prevention & control Animals Benzimidazoles - pharmacology Benzimidazoles - therapeutic use Binge Drinking Cytosolic phospholipase A2 Dentate Gyrus - drug effects Dentate Gyrus - enzymology Dentate Gyrus - pathology Disease Models, Animal Entorhinal Cortex - drug effects Entorhinal Cortex - enzymology Entorhinal Cortex - pathology Enzyme Induction - drug effects Male Nerve Tissue Proteins - biosynthesis Nerve Tissue Proteins - genetics Neurodegeneration Phospholipases A2, Cytosolic - biosynthesis Phospholipases A2, Cytosolic - genetics Poly(ADP-Ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Rats Rats, Sprague-Dawley Veliparib |
| title | PARP inhibition in vivo blocks alcohol-induced brain neurodegeneration and neuroinflammatory cytosolic phospholipase A2 elevations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T00%3A09%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PARP%20inhibition%20in%20vivo%20blocks%20alcohol-induced%20brain%20neurodegeneration%20and%20neuroinflammatory%20cytosolic%20phospholipase%20A2%20elevations&rft.jtitle=Neurochemistry%20international&rft.au=Kouzoukas,%20Dimitrios%20E.&rft.date=2019-10-01&rft.volume=129&rft.spage=104497&rft.epage=104497&rft.pages=104497-104497&rft.artnum=104497&rft.issn=0197-0186&rft.eissn=1872-9754&rft_id=info:doi/10.1016/j.neuint.2019.104497&rft_dat=%3Cproquest_pubme%3E2250630776%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2250630776&rft_id=info:pmid/31251945&rft_els_id=S0197018619302311&rfr_iscdi=true |